New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
10:40 EDTMNK, QCORShort-seller target Questcor spikes after deal to be bought by Mallinckrodt
Questcor (QCOR) shares are sharply higher this morning after the company agreed to be bought by Mallinckrodt (MNK) in a transaction valued at approximately $5.6B. WHAT'S NEW: Questcor, a biopharmaceutical company whose primary drug, H.P. Acthar Gel, is approved by the FDA for the treatment of 19 indications, will be acquired by Mallinckrodt for about $5.6B, made up of $30.00 per share in cash and 0.897 Mallinckrodt shares for each Questcor share they own. The total consideration equated to approximately $86.10 per Questcor share based on the closing price of Mallinckrodt shares on April 4. After the deal closes, Mallinckrodt shareholders will own approximately 50.5% and former Questcor shareholders will own approximately 49.5% of the combined company's stock. The deal is expected to immediately add to Mallinckrodt's fiscal 2014 adjusted earnings per share and significantly add to fiscal 2015 adjusted EPS. The transaction is targeted to close in the third quarter. On the companies' conference call discussing the merger, Questcor said it believes that its first quarter sales will be "somewhat lower" than the fourth quarter of 2013, but also "substantially higher" than last year's first quarter; the consensus estimate for Q1 revenue is $242.08M. Questcor also said that it sees a "favorable" tax structure and operating cash flow, as well as immediate value for shareholders. Mallinckrodt said sees about a 10% decline in the tax rate with the Questcor deal and believes it will realize immediate tax benefits. Mallinckrodt added that its focus will be on deleveraging in the coming months to allow for strategic acquisitions. WHAT'S NOTABLE: Of the 19 indications approved for Acthar, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. Questcor has been a frequent target of the short-selling blog Citron Research in the past. As recently as March 14, Citron Research claimed Questcor was "deceiving" the FDA and investors, alleging H.P. Acthar Gel's active ingredient is less than 20% of the label specification. PRICE ACTION: Questcor is trading up $11.48, or 16.91%, to $79.35 in mid-morning trading. Meanwhile, Mallinckrodt is down $1.70, or 2.72%, to $60.82.
News For QCOR;MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
08:39 EDTMNKMallinckrodt price target lowered to $97 from $114 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Mallinckrodt to $97 after the company issued an outlook for FY16. The outlook is positive, as it implies mid-single digit organic growth from key brands, Gerberry tells investors in a research note. He keeps an Outperform rating on the name.
07:23 EDTMNKEuropean Committee Treatment & Research in Multiple Sclerosis holds meeting
Subscribe for More Information
06:44 EDTMNKMallinckrodt price target lowered to $104 from $140 at Piper Jaffray
Piper Jaffray analyst David Amsellem lowered his price target for Mallinckrodt to $104 citing "recent market realities." The analyst says the company's FY16 guidance contained no surprises and he views the stock as attractively valued at current levels. Amsellem keeps an Overweight rating on the name.
October 6, 2015
09:22 EDTMNKOn The Fly: Pre-market Movers
UP AFTER EARNINGS: PepsiCo (PEP), up 2.6%. ALSO HIGHER: PMC-Sierra (PMCS), up 33.8% after being acquired by Skyworks (SWKS)... Skyworks is up 2.5%... MagneGas (MNGA), up 8.9% after receiving order from a U.S. Army contractor... Exelixis (EXEL), up 5.9% after the phase 3 pivotal trial of cobimetinib met its secondary endpoint... DuPont (DD), up 6.1% after CEO and chair Ellen Kullman retires... Mallinckrodt (MNK), up 3% after providing fiscal 2016 guidance and a business update in a conference call. LOWER: EXACT Sciences (EXAS), down 34.7% after Cologuard included as an alternative screen test under the U.S. Preventive Services Task Force draft guidelines... Illumina (ILMN), down 17.7% after providing third quarter, fourth quarter, and fiscal 2015 guidance... Tesla (TSLA), down 2.5% after Model X forecasts were lowered at Morgan Stanley and the firm cut its price target to $450.
07:43 EDTMNKMallinckrodt continues to expect to generate $1B in cash annually
Subscribe for More Information
07:43 EDTMNKMallinckrodt wants no more than a third of operating income from single product
Subscribe for More Information
07:42 EDTMNKMallinckrodt says specialty generics business will have difficult comparisons
Subscribe for More Information
07:41 EDTMNKMallinckrodt says Acthar is 'complex product', expects long-term volume growth
Subscribe for More Information
06:54 EDTMNKMallinckrodt to hold a conference call
Management holds a business update conference call on October 6 at 7:30 am. Webcast Link
06:10 EDTMNKMallinckrodt sees FY16 net sales from Specialty Brands up at least 30%
Subscribe for More Information
06:06 EDTMNKMallinckrodt sees FY16 adjusted EPS $7.70-$8.20, consensus $8.00
Subscribe for More Information
October 5, 2015
18:56 EDTMNKOn The Fly: After Hours Movers
HIGHER: Regulus Therapeutics (RGLS), up 8.7% after the company announced that it will present new preclinical data on RG-012 for kidney disease... Palatin Technologies (PTN), up 9.6% after director Robert deVeer Jr. buys 10,000 shares of common stock... Arena Pharmaceuticals (ARNA), up 4.7% after CEO Jack Lief announced his retirement and Harry Hixson was named interim CEO... DuPont (DD), up 5.9% after CEO and chair Ellen Kullman retires... Ruckus Wireless (RKUS), up 4.9% after joining the S&P 600... Starz (STRZA), up 10.1% after the LA Times reports that Lionsgate (LGF) is in advanced talks to merge with Starz. DOWN AFTER EARNINGS: Container Store (TCS), down 10.4%. ALSO LOWER: Sarepta Therapeutics (SRPT), down 3.8% after filing to sell $125M of common stock... Haemonetics (HAE), down 12.2% after lowering its fiscal 2016 outlook... Energy XXI (EXXI), down 8.3% after filing a $500M mixed securities shelf... Mallinckrodt (MNK), down 1.6% after announcing that it will provide a business update and financial guidance for the fiscal year ending September 30, 2016, on an investor call on October 6.
17:58 EDTMNKMallinckrodt down 1.9% after announcing business update conference call
Mallinckrodt announced that it will provide a business update and financial guidance for the fiscal year ending September 30, 2016, on an investor call on October 6, 2015. Mallinckrodt will also provide recast historical financial information reflecting the reclassification of its CMDS business to discontinued operations. The company announced plans to sell its CMDS business to Guerbet in late July 2015, with a closing expected in Q1 of FY16.
15:04 EDTMNKMallinckrodt management to meet with JPMorgan
Subscribe for More Information
September 29, 2015
10:00 EDTMNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:18 EDTMNKMallinckrodt initiated with a Neutral at Nomura
Target $100.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use